Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24921005 | 0.86 | CCNA2 (0.38) | FGFR4CCNA2CDK2PIM1TTK | |
| SCHEMBL14496907 | 0.86 | CYP2C9 (0.43) | FGFR4CCNA2CDK2KDR | |
| SCHEMBL18818956 | 0.84 | FGFR4 (0.37) | FGFR4CCNA2CDK2HTTPIM1 | |
| SCHEMBL19498170 | 0.80 | FGFR4 (0.38) | FGFR4CCNA2CDK2HTTPIM1 | |
| SCHEMBL1503877 | 0.77 | MEN1 (0.42) | CCNA2CDK2PIM1TTKPIM2 | |
| SCHEMBL16474030 | 0.73 | SMN1; SMN2 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL16644224 | 0.73 | HRH4 (0.47) | MEN1KMT2AKDRKDM4EALDH1A1 | |
| SCHEMBL1528593 | 0.73 | CCNA2 (0.43) | FGFR4CCNA2CDK2HTTMEN1 | |
| SCHEMBL17466615 | 0.72 | CCNA2 (0.44) | CCNA2CDK2HTTMEN1KMT2A | |
| SCHEMBL741949 | 0.71 | CCNA2 (0.53) | CCNA2CDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | FGFR4 3478/4885CCNA2 2692/4885CDK2 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.